Forum Focus

Current biomarker testing paradigms in breast cancer, and how emerging neoadjuvant/adjuvant strategies in EBC and therapy selection and sequencing in MBC are reshaping real-world treatment decisions

Format

Immersive and discussion-driven. Faculty open the conversation; the room works through what the data actually means in practice. No slides-at-you lectures. Structured as one general session plus two practice-management sessions

Healthcare Provider Role

Just bring your real-world experience with biomarker testing, treatment selection, and sequencing decisions. No prep, no pre-reads, no homework — that lived experience is exactly what makes the exchange work.

Time Commitment

Arrival Friday evening; full day program Saturday. 

One general session plus two practice management sessions - approximately 6 hours total